GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan Keqian Biology Co Ltd (SHSE:688526) » Definitions » Equity-to-Asset

Wuhan Keqian Biology Co (SHSE:688526) Equity-to-Asset : 0.85 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Wuhan Keqian Biology Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Wuhan Keqian Biology Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥3,901.8 Mil. Wuhan Keqian Biology Co's Total Assets for the quarter that ended in Mar. 2024 was ¥4,618.4 Mil. Therefore, Wuhan Keqian Biology Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.85.

The historical rank and industry rank for Wuhan Keqian Biology Co's Equity-to-Asset or its related term are showing as below:

SHSE:688526' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7   Med: 0.82   Max: 0.87
Current: 0.85

During the past 8 years, the highest Equity to Asset Ratio of Wuhan Keqian Biology Co was 0.87. The lowest was 0.70. And the median was 0.82.

SHSE:688526's Equity-to-Asset is ranked better than
74.87% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs SHSE:688526: 0.85

Wuhan Keqian Biology Co Equity-to-Asset Historical Data

The historical data trend for Wuhan Keqian Biology Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Keqian Biology Co Equity-to-Asset Chart

Wuhan Keqian Biology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.82 0.87 0.85 0.80 0.82

Wuhan Keqian Biology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.81 0.80 0.82 0.85

Competitive Comparison of Wuhan Keqian Biology Co's Equity-to-Asset

For the Biotechnology subindustry, Wuhan Keqian Biology Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Keqian Biology Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan Keqian Biology Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Wuhan Keqian Biology Co's Equity-to-Asset falls into.



Wuhan Keqian Biology Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Wuhan Keqian Biology Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3835.627/4671.249
=0.82

Wuhan Keqian Biology Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=3901.802/4618.384
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Keqian Biology Co  (SHSE:688526) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Wuhan Keqian Biology Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Wuhan Keqian Biology Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Keqian Biology Co (SHSE:688526) Business Description

Traded in Other Exchanges
N/A
Address
No. 419, Gaoxin 2nd Road, Donghu New Technology Development Zone, Hubei Province, Wuhan, CHN, 430073
Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.
Executives
Hao Gen Xi Core technical personnel
Zhang Hua Wei Core technical personnel
Zhou Ming Guang Core technical personnel
Zou Tian Tian senior management
Xu Gao Yuan Director
Chen Guan Ping Director

Wuhan Keqian Biology Co (SHSE:688526) Headlines

No Headlines